POINT logo light blue (png).png
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
January 12, 2023 08:30 ET | POINT Biopharma
INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
November 29, 2022 07:30 ET | POINT Biopharma
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model ...
POINT logo light blue (png).png
POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
November 14, 2022 07:15 ET | POINT Biopharma
INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 14, 2022 07:00 ET | POINT Biopharma
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
POINT-Logo-Colour (blue).png
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress
October 17, 2022 08:30 ET | POINT Biopharma
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA...
POINT-Logo-Colour (blue).png
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
September 16, 2022 16:30 ET | POINT Biopharma
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET | POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
September 10, 2022 03:05 ET | POINT Biopharma
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...
POINT-Logo-Colour (blue).png
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
September 04, 2022 18:10 ET | POINT Biopharma
INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
August 18, 2022 16:30 ET | POINT Biopharma
In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at...